Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKBA
CUSIPN/A
Phone617-871-2098
Debt
Debt-to-Equity RatioN/A
Current Ratio2.89
Quick Ratio2.89
Price-To-Earnings
Trailing P/E Ratio-6.07
Forward P/E Ratio-5.07
P/E GrowthN/A
Sales & Book Value
Annual Sales$177.98 million
Price / Sales3.44
Cash FlowN/A
Price / CashN/A
Book Value$2.52 per share
Price / Book4.27
Profitability
EPS (Most Recent Fiscal Year)($1.77)
Net Income$-76,910,000.00
Net Margins-27.48%
Return on Equity-47.15%
Return on Assets-15.05%
Miscellaneous
Employees114
Outstanding Shares56,880,000
Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions
What is Akebia Therapeutics' stock symbol?
Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
How were Akebia Therapeutics' earnings last quarter?
Akebia Therapeutics Inc (NASDAQ:AKBA) posted its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.01. The biopharmaceutical company had revenue of $45.93 million for the quarter, compared to the consensus estimate of $47.80 million. Akebia Therapeutics had a negative return on equity of 47.15% and a negative net margin of 27.48%. View Akebia Therapeutics' Earnings History.
When is Akebia Therapeutics' next earnings date?
What price target have analysts set for AKBA?
6 brokerages have issued 12 month price targets for Akebia Therapeutics' shares. Their predictions range from $17.00 to $30.00. On average, they anticipate Akebia Therapeutics' stock price to reach $23.80 in the next twelve months. View Analyst Ratings for Akebia Therapeutics.
What are Wall Street analysts saying about Akebia Therapeutics stock?
Here are some recent quotes from research analysts about Akebia Therapeutics stock:
- 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (6/19/2018)
- 2. Mizuho analysts commented, "We had a chance to catch up with CEO John Butler yesterday at the Bio CEO & Investor Conference. We summarize our key takeaways below. Akebia also provided an update on the Vadadustat development program yesterday morning including an expansion of the ongoing phase 2 For2ward and phase 3 Trilo2gy trials in collaboration with Otsuka (TYO:4578, Non rated). While this will delay the timeline for topline data in both programs, we see it as a positive overall as the company will now incorporate additional relevant endpoints with a greater number of patients for better positioning in commercialization. The timeline for data-readouts in the two pivotal Pro2tect and Inno2vate trials remains unchanged." (2/13/2018)
Who are some of Akebia Therapeutics' key competitors?
Some companies that are related to Akebia Therapeutics include Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akcea Therapeutics (AKCA), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), Endo International (ENDP), Insmed (INSM), Spectrum Pharmaceuticals (SPPI), Prestige Brands (PBH), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Akorn (AKRX), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT) and Myokardia (MYOK).
Who are Akebia Therapeutics' key executives?
Akebia Therapeutics' management team includes the folowing people:
- Mr. John P. Butler, CEO, Pres & Director (Age 54)
- Mr. Michel Dahan, Sr. VP & Chief Bus. Officer (Age 39)
- Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 56)
- Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 50)
- Ms. Theresa McNeely, Sr. VP - Corp. Communications and Investor Relations (Age 54)
Has Akebia Therapeutics been receiving favorable news coverage?
News coverage about AKBA stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akebia Therapeutics earned a news impact score of 0.06 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.75 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Akebia Therapeutics' major shareholders?
Akebia Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.56%), Eagle Asset Management Inc. (4.79%), Millennium Management LLC (1.16%), DAFNA Capital Management LLC (1.07%), Northern Trust Corp (0.91%) and American Century Companies Inc. (0.88%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.
Which institutional investors are selling Akebia Therapeutics stock?
AKBA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Wells Fargo & Company MN and Citigroup Inc.. Company insiders that have sold Akebia Therapeutics company stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.
Which institutional investors are buying Akebia Therapeutics stock?
AKBA stock was acquired by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Artal Group S.A., BlackRock Inc., CVI Holdings LLC, Stanley Laman Group Ltd., PNC Financial Services Group Inc., Point72 Asset Management L.P. and Spark Investment Management LLC. View Insider Buying and Selling for Akebia Therapeutics.
How do I buy shares of Akebia Therapeutics?
Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akebia Therapeutics' stock price today?
One share of AKBA stock can currently be purchased for approximately $10.75.
How big of a company is Akebia Therapeutics?
Akebia Therapeutics has a market capitalization of $616.61 million and generates $177.98 million in revenue each year. The biopharmaceutical company earns $-76,910,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Akebia Therapeutics employs 114 workers across the globe.
How can I contact Akebia Therapeutics?
Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]
MarketBeat Community Rating for Akebia Therapeutics (AKBA)
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
